Company research
ORASURE TECHNOLOGIES INC
CIK 1116463Updated Sep 29, 2026
SecurityOSUR · NASDAQ · equity
OSUR price & chart
Loading TradingView…
NASDAQ:OSUR on TradingView ↗About the company
OraSure Technologies, Inc. (“OraSure” and “OTI”) transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are. OraSure improves access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. Together with its wholly-owned subsidiaries, DNA Genotek Inc., Sherlock Biosciences, Inc., and BioMedomics, Inc., OTI is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physicians’ offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct to consumers. For more information on OraSure Technologies, please visit www.orasure.com
In the news
OraSure to Announce Second Quarter 2026 Financial Results and Host Earnings Call on August 5th ↗
Recent filings
SCHEDULE 13D filing
SCHEDULE 13G filing
S-8 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 403,168,000Source | 479,659,000Source | 482,845,000Source | 444,708,000Source |
| Property, Plant and Equipment, NetUSD | 39,179,000Source | 45,105,000Source | 45,420,000Source | 59,413,000Source |
| GoodwillUSD | 43,363,000Source | 40,330,000Source | 35,696,000Source | 35,104,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 19,046,000Source | 17,435,000Source | — | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 199,278,000Source | 267,763,000Source | 290,407,000Source | 83,980,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 22,203,000Source | 23,816,000Source | 40,171,000Source | 70,797,000Source |
| Inventory, NetUSD | 31,060,000Source | 34,197,000Source | 47,614,000Source | 96,232,000Source |
| Assets, CurrentUSD | 261,908,000Source | 333,220,000Source | 386,459,000Source | 325,718,000Source |
| Operating Lease, Right-of-Use AssetUSD | 11,996,000Source | 13,442,000Source | 12,270,000Source | 10,399,000Source |
| Other Assets, NoncurrentUSD | 1,303,000Source | 1,526,000Source | 1,218,000Source | 1,087,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 62,341,000Source | 69,321,000Source | 52,174,000Source | 81,084,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | — |
| Common Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source |
| Retained Earnings (Accumulated Deficit)USD | -172,162,000Source | -103,431,000Source | -83,931,000Source | -138,387,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -18,404,000Source | -24,360,000Source | -14,941,000Source | -18,435,000Source |
| Stockholders' Equity Attributable to ParentUSD | 340,827,000Source | 410,338,000Source | 430,671,000Source | 363,624,000Source |
| Additional Paid in Capital, Common StockUSD | 531,393,000Source | 538,129,000Source | 529,543,000Source | 520,446,000Source |
| Liabilities and EquityUSD | 403,168,000Source | 479,659,000Source | 482,845,000Source | 444,708,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 39,795,000Source | 33,483,000Source | 39,536,000Source | 70,392,000Source |
| Operating Lease, Liability, CurrentUSD | 2,164,000Source | 2,129,000Source | 1,577,000Source | 1,764,000Source |
| Accounts Payable, CurrentUSD | 6,521,000Source | 8,173,000Source | 13,151,000Source | 39,349,000Source |
| Operating Lease, Liability, NoncurrentUSD | 10,870,000Source | 12,321,000Source | 11,162,000Source | 9,101,000Source |
| Deferred Income Tax Liabilities, NetUSD | — | 0Source | 554,000Source | 408,000Source |
| Other Liabilities, NoncurrentUSD | 2,243,000Source | 494,000Source | 696,000Source | 581,000Source |
| Additional Financial Items | ||||
| AOCI, Debt Securities, Available-for-sale, Adjustment, after TaxUSD | — | — | — | 220,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | 554,000Source | 408,000Source |
| Short-term InvestmentsUSD | — | — | 0Source | 26,867,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | -19,500,000Source | 53,655,000Source | -17,934,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 10,192,000Source | 10,872,000Source | 20,936,000Source | 15,308,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 10,147,000Source | 11,920,000Source | 10,729,000Source | 11,622,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -1,949,000Source | -15,872,000Source | -31,116,000Source | 25,162,000Source |
| Increase (Decrease) in InventoriesUSD | -3,562,000Source | -13,096,000Source | -48,228,000Source | 43,048,000Source |
| Increase (Decrease) in Accounts PayableUSD | -1,720,000Source | -7,577,000Source | -26,976,000Source | 3,963,000Source |
| Deferred Income Tax Expense (Benefit)USD | 1,853,000Source | -657,000Source | 102,000Source | -1,651,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -49,023,000Source | 27,374,000Source | 141,583,000Source | -47,202,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | 3,613,000Source | 5,037,000Source | — | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -6,810,000Source | -39,026,000Source | 66,154,000Source | 21,085,000Source |
| Payments for (Proceeds from) Other Investing ActivitiesUSD | — | — | 0Source | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | 4,197,000Source | 3,797,000Source | 5,802,000Source | 6,774,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 1,843,000Source | — | — | — |
| Payments for Repurchase of Common StockUSD | 15,040,000Source | 3,548,000Source | 1,901,000Source | 2,254,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -16,944,000Source | -4,176,000Source | -3,023,000Source | -3,828,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -68,485,000Source | -22,644,000Source | 206,427,000Source | -32,782,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 1,841,000Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 10,147,000Source | 11,920,000Source | — | — |
| Amortization of Intangible AssetsUSD | 300,000Source | 700,000Source | 2,000,000Source | 2,269,000Source |
| DepreciationUSD | 9,900,000Source | 9,800,000Source | 17,900,000Source | 11,740,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -900,000Source | 1,200,000Source | -100,000Source | 1,553,000Source |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | -365,000Source | 263,000Source | -103,000Source | 161,000Source |
| Gain (Loss) on Disposition of AssetsUSD | 725,000Source | -563,000Source | 0Source | -729,000Source |
| Gain (Loss) on Disposition of Other AssetsUSD | 725,000Source | — | — | — |
| General and Administrative ExpenseUSD | 47,677,000Source | 46,215,000Source | 58,191,000Source | 68,206,000Source |
| GoodwillUSD | 43,363,000Source | 40,330,000Source | 35,696,000Source | 35,104,000Source |
| Goodwill, Impairment LossUSD | — | — | 0Source | 3,604,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | -2,344,000Source | -1,700,000Source | — | — |
| Income Tax Expense (Benefit)USD | 1,801,000Source | 1,799,000Source | 2,603,000Source | 1,458,000Source |
| Investment Income, InterestUSD | 8,078,000Source | 11,469,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -68,731,000Source | -19,500,000Source | 53,655,000Source | -17,934,000Source |
| Operating ExpensesUSD | 120,167,000Source | 107,640,000Source | 138,968,000Source | 170,594,000Source |
| Operating Lease, Impairment LossUSD | — | 1,200,000Source | — | — |
| Other Nonoperating Income (Expense)USD | 229,000Source | -380,000Source | 23,574,000Source | 6,481,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | 0Source | 53,052,000Source | 102,440,000Source | 47,415,000Source |
| Proceeds from Stock Options ExercisedUSD | 0Source | 214,000Source | 269,000Source | 15,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 115,021,000Source | 185,827,000Source | 405,472,000Source | 387,479,000Source |
| Cost of RevenueUSD | 66,823,000Source | 106,437,000Source | 233,820,000Source | 239,842,000Source |
| Operating Income (Loss)USD | -71,969,000Source | -28,250,000Source | 32,684,000Source | -22,957,000Source |
| Other Nonoperating Income (Expense)USD | 229,000Source | -380,000Source | 23,574,000Source | 6,481,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -64,586,000Source | -16,001,000Source | 56,258,000Source | -16,476,000Source |
| Income Tax Expense (Benefit)USD | 1,801,000Source | 1,799,000Source | 2,603,000Source | 1,458,000Source |
| Net Income (Loss) Attributable to ParentUSD | -68,731,000Source | -19,500,000Source | 53,655,000Source | -17,934,000Source |
| Earnings Per Share, BasicUSD per share | -0.94Source | -0.26Source | 0.73Source | -0.25Source |
| Earnings Per Share, DilutedUSD per share | -0.94Source | -0.26Source | 0.72Source | -0.25Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 73,485,000Source | 74,434,000Source | 73,348,000Source | 72,505,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 73,485,000Source | 74,434,000Source | 74,389,000Source | 72,505,000Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 300,000Source | 700,000Source | 2,000,000Source | 2,269,000Source |
| Current Income Tax Expense (Benefit)USD | -52,000Source | 2,456,000Source | 2,501,000Source | 3,109,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -900,000Source | 1,200,000Source | -100,000Source | 1,553,000Source |
| General and Administrative ExpenseUSD | 47,677,000Source | 46,215,000Source | 58,191,000Source | 68,206,000Source |
| Goodwill, Impairment LossUSD | — | — | 0Source | 3,604,000Source |
| Gross ProfitUSD | 48,198,000Source | 79,390,000Source | 171,652,000Source | 147,637,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -62,742,000Source | -21,523,000Source | 61,671,000Source | -7,912,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | -2,344,000Source | -1,700,000Source | — | — |
| Investment Income, InterestUSD | 8,078,000Source | 11,469,000Source | — | — |
| Operating ExpensesUSD | 120,167,000Source | 107,640,000Source | 138,968,000Source | 170,594,000Source |
| Research and Development ExpenseUSD | 42,528,000Source | 26,047,000Source | 33,728,000Source | 36,237,000Source |
| Selling and Marketing ExpenseUSD | 26,117,000Source | 30,986,000Source | 36,319,000Source | 49,238,000Source |
Filing attachments
ex992_q1-26investorupdat.htm · 8-K · 2026-05-06
EX-99.2 3 ex992_q1-26investorupdat.htm EX-99.2 ex992_q1-26investorupdat OraSure Investor Update May 2026 EXHIBIT 99.2 © 2026 OraSure Technologies, Inc. 2OTI Proprietary Disclaimers Forward-Looking Statements: This presentation of OraSure Technologies, Inc. (the “Company” or “OraSure”) contains certain “forward-looking statements” within the meaning of federal securities laws, including with respect to products, product candidate development and manufacturing activities, regulatory submissi…
Read attachment ↗d144249dex991.htm · 8-K · 2026-04-17
EX-99.1 3 d144249dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 On April 16, 2026, OraSure Technologies, Inc. issued the following press release: FOR IMMEDIATE RELEASE OraSure Technologies Appoints John D. Bertrand to its Board of Directors Enters into Cooperation Agreement with Altai Capital Board to Seek Shareholder Approval for Declassification at the 2026 Annual Meeting BETHLEHEM, Pa., April 16, 2026 - OraSure Technologies, Inc. (“OraSure” and “OTI”) (NASDAQ: OSUR), a leader in point-of-…
Read attachment ↗d138279dex991.htm · 8-K · 2026-03-30
EX-99.1 2 d138279dex991.htm EX-99.1 EX-99.1 OraSure: The Facts Altai Capital has made several misleading claims that serve as the basis for its efforts to replace two independent directors on OraSure’s Board. This presentation sets the record straight on the facts. March 2026 Exhibit 99.1 Strategy & Growth Outlook OraSure is executing a focused strategy with near-term catalysts expected to drive revenue growth, margin expansion, and profitability Public health funding environment stabilizi…
Read attachment ↗